DiagnoCure, Lab21 Ink UK Sales Pact | GenomeWeb

NEW YORK (GenomeWeb News) - DiagnoCure said today that Lab21 will sell its colorectal cancer staging test in the UK and Ireland.

Under the exclusive agreement, Lab21 will promote and sell the Previstage GCC Colorectal Cancer Staging Test in the two countries as part of its oncology testing services. DiagnoCure said that it will process the patient samples in its clinical lab in the US.

The company said that around 9,600 people in the UK could benefit from using the test for planning treatment staging each year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: CRISPR-based barcodes to trace cell lineages, and more.

The director of the National Institutes of Health Francis Collins sang the national anthem this week before a baseball game.

French researchers criticize unexpected government plan to cut research funding, ScienceInsider reports.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.